MRNA

#624
Moderna, Inc. - Common Stock
47.1 3 USD
-0.92%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
46.82
47.43
Range Annuel
22.29
59.55
Changement quotidien
-0.92%
Changement Mensuel
+1.99%
Evolution sur 6 mois
+88.14%
Changement Annuel
+78.52%
Clôture Précédente
47.5 7
Open
47.2 8
Low
46.8 2
High
47.4 3
Volume
871
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 18.7 B
  • Employee 4 700
  • Founded N/A
  • CEO Stéphane Bancel
  • Website www.modernatx.com
  • Headquarter Delaware, United States
  • FIGI BBG003PHHZT1
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-4.06
ratio cours/chiffre d'affaires
5.9

Moderna, Inc. - Common Stock

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.

Nouvelles